We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.70 | 33.50 | 33.70 | 33.95 | 33.40 | 33.95 | 565,278 | 12:48:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 198.24 | 182.03M |
TIDMAPH
RNS Number : 8801O
Alliance Pharma PLC
05 October 2023
For immediate release 5 October 2023
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Grant of Options to Directors
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Board has issued options over an aggregate of 2,281,643 ordinary shares of 1 pence each in the Company, on the recommendation of the Company's Remuneration Committee, to the PDMRs detailed below, pursuant to the Company's Long-Term Incentive Plan 2019.
Peter Butterfield, Chief Executive Officer, has been awarded 851,666 share options.
Andrew Franklin, Chief Financial Officer, has been awarded 568,866 share options.
Jeyan Heper, Chief Operating Officer, has been awarded 861,111 share options (250,000 of which have been awarded pursuant to his joining of the Company earlier this year).
The awards have been granted at nil-cost and become exercisable on 4 October 2026 subject always to continued employment and the satisfaction of performance conditions based on EPS, TSR and ROCE targets.
The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:
Name Share Options granted Total no. of options over ordinary shares now held Peter Butterfield 851,666 4,057,553 ---------------------- ---------------------- Andrew Franklin 568,866 2,845,373 ---------------------- ---------------------- Jeyan Heper 861,111 861,111 ---------------------- ----------------------
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person discharging managerial responsibilities.
Details of the person discharging managerial responsibilities/person 1 closely associated a) Name Mr Peter Butterfield --------------------------- ------------------------------------------------ Reason for the notification 2 ----------------------------------------------------------------------------- a) Position/status Chief Executive Officer - PDMR --------------------------- ------------------------------------------------ b) Initial notification Initial Notification /Amendment --------------------------- ------------------------------------------------ Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------- a) Name Alliance Pharma plc --------------------------- ------------------------------------------------ b) Legal Entity N/A Identifier --------------------------- ------------------------------------------------ Details of the transaction(s): section to be repeated for 4 (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------- a) Description Ordinary shares of 1.0 pence each of the financial instrument, type of instrument ISIN: GB0031030819 Identification code --------------------------- ------------------------------------------------ b) Nature of the Grant of Options transaction --------------------------- ------------------------------------------------ c) Currency GBP --------------------------- ------------------------------------------------ d) Price(s) and Exercise Price No. of share options volume(s) (p) --------------------------- -------------------- -------------------------- Nil 851,666 ----------------------------------------------------- -------------------------- e) Aggregated Grant of 851,666 options to acquire ordinary information shares of 1 pence each at nil-cost. - Aggregated volume - Price - Aggregated total --------------------------- ------------------------------------------------ f) Date of the 4 October 2023 transaction --------------------------- ------------------------------------------------ g) Place of the Outside of trading venue transaction --------------------------- ------------------------------------------------ Details of the person discharging managerial responsibilities/person 1 closely associated a) Name Mr Andrew Franklin --------------------------- ------------------------------------------------ Reason for the notification 2 ----------------------------------------------------------------------------- a) Position/status Chief Financial Officer - PDMR --------------------------- ------------------------------------------------ b) Initial notification Initial Notification /Amendment --------------------------- ------------------------------------------------ Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------- a) Name Alliance Pharma plc --------------------------- ------------------------------------------------ b) Legal Entity N/A Identifier --------------------------- ------------------------------------------------ Details of the transaction(s): section to be repeated for 4 (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------- a) Description Ordinary shares of 1.0 pence each of the financial instrument, type of instrument ISIN: GB0031030819 Identification code --------------------------- ------------------------------------------------ b) Nature of the Grant of Options transaction --------------------------- ------------------------------------------------ c) Currency GBP --------------------------- ------------------------------------------------ d) Price(s) and Exercise Price No. of share options volume(s) (p) --------------------------- -------------------- -------------------------- Nil 568,866 ----------------------------------------------------- -------------------------- e) Aggregated Grant of 568,866 options to acquire ordinary information shares of 1 pence each at nil-cost. - Aggregated volume - Price - Aggregated total --------------------------- ------------------------------------------------ f) Date of the 4 October 2023 transaction --------------------------- ------------------------------------------------ g) Place of the Outside of trading venue transaction --------------------------- ------------------------------------------------ Details of the person discharging managerial responsibilities/person 1 closely associated a) Name Mr Jeyan Heper --------------------------- ----------------------------------------------- Reason for the notification 2 ---------------------------------------------------------------------------- a) Position/status Chief Operating Officer - PDMR --------------------------- ----------------------------------------------- b) Initial notification Initial Notification /Amendment --------------------------- ----------------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor ---------------------------------------------------------------------------- a) Name Alliance Pharma plc --------------------------- ----------------------------------------------- b) Legal Entity N/A Identifier --------------------------- ----------------------------------------------- Details of the transaction(s): section to be repeated for 4 (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description Ordinary shares of 1.0 pence each of the financial instrument, type of instrument ISIN: GB0031030819 Identification code --------------------------- -----------------------------------------------
b) Nature of the Grant of Options transaction --------------------------- ----------------------------------------------- c) Currency GBP --------------------------- ----------------------------------------------- d) Price(s) and Exercise Price No. of share options volume(s) (p) --------------------------- -------------------- ------------------------- Nil 861,111 ----------------------------------------------------- ------------------------- e) Aggregated Grant of 861,111options to acquire ordinary information shares of 1 pence each at nil-cost. - Aggregated volume - Price - Aggregated total --------------------------- ----------------------------------------------- f) Date of the 4 October 2023 transaction --------------------------- ----------------------------------------------- g) Place of the Outside of trading venue transaction --------------------------- -----------------------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966 Head of Investor Relations: Cora McCallum + 44 (0)1249 705168 ir@allianceph.com + 44 (0)20 7466 Buchanan 5000 Mark Court / Sophie Wills / Hannah Ratcliff alliancepharma@buchanan.uk.com Numis Securities Limited (Nominated Adviser + 44 (0)20 7260 and Joint Broker) 1000 Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah + 44 (0)20 7597 Investec Bank plc (Joint Broker) 5970 Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company . Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions .
Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHUPGMWUUPWGAA
(END) Dow Jones Newswires
October 05, 2023 11:39 ET (15:39 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions